Valneva operates multi-site manufacturing infrastructure across Scotland, Sweden, and Austria, positioning it to serve global markets across North America and Europe. The company is transitioning from travel vaccine focus to address significant unmet medical needs in endemic infectious diseases, with recent positive clinical data supporting advancement of pipeline programs toward market expansion and diversification.
Cyborg Score Rationale
Valneva demonstrates solid fundamentals with approved commercial products generating growing revenues and advancing clinical pipelines. However, regulatory setbacks (FDA suspension of IXCHIQ), operational complexities, and the need for significant capital investment to commercialize pipeline candidates limit upside potential in the near-to-medium term.
Top Insights
2024 revenue was $169.58 million, an increase of 10.32% compared to the previous year's $153.71 million
Analyst consensus rates the stock as "Strong Buy" with a 12-month price target of $15.75, implying 56.87% upside
Advanced pipeline includes VLA15 for Lyme disease, S4V2 for shigellosis, VLA1601 for Zika, and programs targeting human metapneumovirus, C. difficile infection, and Epstein-Barr virus
Recent regulatory headwinds including FDA suspension of IXCHIQ require careful monitoring; company navigating commercialization while managing manufacturing and clinical development complexity